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Abstract
The human papillomavirus (HPV) minor capsid protein L2 is a promising candidate for a broadly protective HPV vaccine yet
the titers obtained in most experimental systems are rather low. Here we examine the potential of empty AAV2 particles
(AAVLPs), assembled from VP3 alone, for display of L2 epitopes to enhance their immunogenicity. Insertion of a neutralizing
epitope (amino acids 17–36) from L2 of HPV16 and HPV31 into VP3 at positions 587 and 453, respectively, permitted
assembly into empty AAV particles (AAVLP(HPV16/31L2)). Intramuscularly vaccination of mice and rabbits with
AAVLP(HPV16/31L2)s in montanide adjuvant, induced high titers of HPV16 L2 antibodies as measured by ELISA. Sera
obtained from animals vaccinated with the AAVLP(HPV16/31L2)s neutralized infections with several HPV types in
a pseudovirion infection assay. Lyophilized AAVLP(HPV16/31L2) particles retained their immunogenicity upon re-
constitution. Interestingly, vaccination of animals that were pre-immunized with AAV2 - simulating the high prevalence of
AAV2 antibodies in the population - even increased cross neutralization against HPV31, 45 and 58 types. Finally, passive
transfer of rabbit antisera directed against AAVLP(HPV16/31L2)s protected naı ¨ve mice from vaginal challenge with HPV16
pseudovirions. In conclusion, AAVLP(HPV16/31L2) particles have the potential as a broadly protective vaccine candidate
regardless of prior exposure to AAV.
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Introduction
Persistent high-risk human papillomavirus (HPV) infection has
been linked to the development of cervical cancer [1]. Attempts to
prevent infection with the most prevalent high risk HPV types –
HPV16 and HPV18 – led to the development of two highly
efficacious HPV vaccines that comprise virus-like particles (VLPs)
assembled from the major capsid protein L1. However these
vaccines target only two of the 15 high-risk HPV types, responsible
for 70–80% of cervical cancer cases. The prevention of 96% of
cervical cancer would require the immunity against at least 7 high-
risk HPV types (HPV16, 18, 31, 33, 45, 52 and 58), but this
increases the cost and complexity of manufacture [2]. Future
vaccines should therefore attempt to extend immunization against
other high-risk HPV types. For broad application also in
developing countries they should be provided inexpensively in
a temperature stable formulation.
The minor capsid protein L2 harbors several regions that can be
targeted by neutralizing antibodies [3–5]. One of which, located at
amino acid position 17–36 comprises a major cross-neutralizing
epitope and thus represents an attractive candidate antigen for
broadly protective vaccination [6–8]. However, the major
challenge in using the L2 protein as vaccine antigen is its rather
poor immunogenicity compared to L1 VLP. It has been attempted
to increase the immunogenicity of L2, by the use of different
scaffolds [3,6,9], linking of L2 to TLR agonists [10] or by using
a concatenated L2 N-terminal fragment [11].
Adeno-associated virus (AAV) belongs to the parvovirus family
harboring a single-stranded DNA genome of approximately
4.7 kb. AAV particles that are very stable over a wide range of
pH and temperature have a diameter of 25 nm, and are composed
of 60 capsid protein subunits, designated VP1, VP2, and VP3 [12].
A recent study demonstrated that assembly of AAV capsids
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protein (AAP) [13]. Moreover, co-expression of VP3 with AAP
allows the efficient production of virus-like particles (AAVLPs)
composed of only the major capsid protein VP3 [13]. These
capsids adopt an identical external capsid structure as VP1, VP2
and VP3 containing capsids [14] and represent a preferred scaffold
for peptide vaccination, because of their simplicity and their
inability to transfer genes which may inadvertently have been
packaged in such AAVLPs. Due to the highly structured and
repetitive presentation of epitopes on the capsid (60 times),
combined with the intrinsic immunogenicity of AAV [15], potent
B-cell responses against the peptide presented at immunogenic
capsid positions can be expected. So far, AAV capsids have not
been analyzed for this purpose.
Here we show for the first time the potential to present B-cell
epitopes on AAVLP capsid surface. We generated AAVLPs
displaying HPV16 L2 epitopes in position 587 and HPV31 L2
epitopes in position 453. Our results demonstrate cross-neutral-
izing responses against several HPV types and therefore suggest
AAVLP(HPV16/31L2) particles as a broadly protective vaccine
candidate.
Results
Production of AAVLP(HPV16/31L2) Particles
Adeno-associated virus serotype 2 (AAV2) capsids tolerate
insertion of peptides in their antigenic region at position 587 or
453 [16–22] that are attractive sites for presenting B-cell
epitopes.The expression of only two AAV proteins, VP3 and
AAP, allows the formation of VP3-VLPs (AAVLPs). These
observations suggest that recombinant AAVLPs could be gener-
ated with insertions of peptides in positions 587 and 453. After
immunization with HPV16 L2 peptide 17–36 a broad range of
cross- neutralizing antibodies was generated, but low or no
antibodies against HPV31 [23]. Since HPV L2 17–36 aa
sequences of HPV16 and 31 are clearly different, we incorporated
both HPV L2 peptides into AAVLP particles at position 587 and
453 (figure 1A). Stretches of 3 or 5 glycine residues were added to
the N and C termini of the respective peptides for optimal surface
display and several amino acids resulting from restriction enzyme
sites used for cloning increased the size of inserted peptide
sequences to 35 aa (position 453) and 31 aa (position 587). The
amino acids at positions 585 and 588 were substituted. These
R585A/R588A substitutions increased the titers of AAVLP
particles with inserts. SDS-PAGE and Western blot analysis of
AAVLPs confirmed the identity and size (approximately 66 kDa of
AAVLP(HPV16/31L2) VP3) of the purified protein (figure 1B).
Presentation of the inserted HPV L2 peptides on the AAVLP
particles were demonstrated with L2-specific rabbit sera in a dot
blot assay under native conditions. However, since these sera
cross-react with the HPV16 and HPV31 displayed peptides,
exposure of both of them could not be unambiguously proven. As
shown in figure 1C, proteins assembled into VLPs of ,25–30 nm
in diameter. In conclusion, the insertions of 35 aa (position 453)
and 31 aa (position 587) into the capsid protein did not interfere
with VLP assembly.
Immunogenicity of AAVLP(HPV16/31L2) Particles in
C57BL/6 Mice
In order to analyse the HPV16 L2-specific immune response
induced by AAVLP(HPV16/31L2) particles we immunized
C57BL/6 mice either with a low dose (LD) (1E+11 particles
equivalent to 0.6 mg of protein) or high dose (HD) (5E+12
particles equivalent to 30 mg) with or without adjuvant (+M)
(montanide ISA 51). Thioredoxin-L2(20–38)3 (TrXL2) [3]
(50 mg) was used as positive control, and wtAAVLP particles
served as a negative control. Anti-HPV16 L2 antibodies were
measured by GST-L2 ELISA six weeks after the first immuni-
zation. As shown in figure 2, mice immunized with LD+Mo r
HD+M developed 25 and 50 fold higher HPV16 L2-specific
antibodies titers, respectively, than mice immunized with a LD of
particles without adjuvant. Interestingly, there was little differ-
ence between the mice immunized with LD+M and mice
immunized with HD+M. Sera of all mice vaccinated with
TrXL2+M had HPV16 L2-specific antibodies.
Neutralization was determined by inhibition of gene trans-
duction by pseudovirions (PsV) containing the gene for gaussia
luciferase (gLuc). Transduction was measured by gLuc expression
which is taken as a surrogate of infection. The sera were tested in
serial dilutions from 1:40 to 1:30,720, and a 50% reduction of
gLuc activity was defined as positive neutralization. As shown in
figure 3A, the enhancing effect of the adjuvant was also evident
from the neutralizing activity against HPV16 and HPV31, but the
HPV31-specific neutralization was weaker. Future HPV vaccines
should induce immunity against other high-risk HPV types. We
therefore analysed the ability of our particles to induce cross-
neutralizing antibodies against several PsV (HPV18, HPV45,
HPV52 and HPV58). As shown in figure 3B a similar pattern of
reactivity was observed when the sera were tested for cross-
neutralizing antibodies against HPV18, HPV45, HPV52 and
HPV58. Animals vaccinated with TrXL2+M did not develop
cross-neutralizing antibodies. We conclude from these results that
neutralizing activity against HPV16 induced by the particles is
higher than the one to HPV31. Cross-neutralization can only be
achieved with adjuvanted AAVLPs. Reactivity of sera from mice
immunized with AAVLP(HPV16/31L2) particles was higher than
TrXL2 in C57BL/6 mice.
Immunogenicity of AAVLP(HPV16/31L2) Particles in Balb/
c Mice
Cross-neutralizing activity of AAVLP(HPV16/31L2) was more
closely analyzed in Balb/c mice, to this end animals were
immunized with low dose of AAVLP plus montanide ISA51 two
(LD+M 2x) or three times (LD+M 3x). In order to test the potency
of another adjuvant a group of mice were vaccinated three times
i.m. with low dose of AAVLP together with monophosphoryl
Lipid A (MPL) (LD+MPL). Animals vaccinated with TrXL2 plus
montanide ISA51 (TrXL2+ M) or with one of the two licensed
HPV vaccines, Cervarix
TM and Gardasil
TM (1/10 of the dose
recommended for humans) were used as controls.
A potential challenge for using AAV2-based vaccines in humans
is the naturally acquired immune responses in approximately 80%
of the human population ([24], [25], [15]), as the presence of
antibodies against the AAV capsid may prevent an efficient
vaccination. Therefore we immunized a group of animals with
AAV2 (1E+11 particles/animal) prior to vaccination with AAVLP.
Two and four weeks after pre-immunization, antibodies reacting
with AAV2 capsids were detected by ELISA (titers between 80 and
1000) (figure 4). At week 4 animals were vaccinated with LD+M
3x. Generation of HPV16 L2 specific antibodies was measured by
a GST-L2 ELISA two weeks after the last immunization. As
shown in figure 5, mice immunized with two or three doses of
AAVLPs as well as with TrXL2+M developed comparable high
titers of L2-specific antibodies (.100,000). Interestingly, also after
pre-immunization with AAV similar titer levels were measured.
The requirements for vaccines that are stable at ambient
temperature imply the development of freeze-dried formulations
may be beneficial. Lyophilized and rehydrated AAVLP(HPV16/
AAVLP(HPV16/31L2) Particles as HPV Vaccine
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compared to the unprocessed particles. Animals vaccinated in the
presence of MPL developed around one log lower HPV16 L2-
specific antibody titers (,10,000) than mice which received
montanide ISA51 adjuvanted particles.
Neutralizing activity of the different groups against HPV16 and
HPV31 PsV followed a similar pattern as the titers measured by
ELISA with responses against HPV31 being consistently lower
than against HPV16 (figure 6A). Sera of all mice vaccinated with
TrXL2+M, Cervarix
TM and Gardasil
TM had neutralizing activity
against HPV16 PsV with mean titers of .10000 but not HPV31
Figure 1. Generation and production of AAVLP(HPV16/31L2). A) Schematic presentation of the chimeric VP3 protein with the insertions of
the HPV31 and HPV16 L2 peptides. The amino acid residues refer to the VP1 protein sequence. Solid lines indicate the VP3 protein and open bars the
L2 peptides. B) Analysis of the purified AAVLP(HPV16/31L2) particles by SDS- PAGE, coomassie blue staining and Western blotting with the
monoclonal antibody B1 directed against VP3. Native dot blots with polyclonal rabbit sera to the HPV16 and 31 L2 aa 17–36 peptides, AAVLP particles
and the AAVLP(HPV16/31L2) particles. Dot blots are done in duplets. C) TEM of the purified particles.
doi:10.1371/journal.pone.0039741.g001
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HPV52, HPV58 and BPV PsV were detected, again in a similar
ratio between the groups with neutralizing activity being highest
against HPV18, HPV45 and HPV58 (figure 6B). Most of the
animals immunized with TrXL2+M developed HPV45, HPV52,
HPV58 and BPV cross-neutralizing antibodies. Low level of cross-
reactivity against HPV45 was obtained with 2/5 animals that had
received Cervarix
TM.
In conclusion, Balb/c and C57BL/6 mice responded with
similar HPV16- specific titers to immunization with
AAVLP(HPV16/31L2) particles, but the cross-neutralizing titers
were higher in Balb/c mice. Remarkably, pre-existing AAV
antibodies did not prevent the induction of humoral responses
against HPV. Lyophilized particles retained immunogenicity after
reconstitution, albeit at somewhat lower level. In both mouse
strains immune responses against HPV16 induced by AAVLP is
higher than against HPV31, suggesting that the HPV31 L2-
epitope inserted at position 453 is less immunogenic than the
HPV16 L2-epitope inserted at aa 587.
Immunogenicity of AAVLP(HPV16/31L2) Particles in
Rabbits
In addition, three ZIKA hybrid rabbits were immunized four
times with AAVLP(HPV16/31L2) particles (2E+12 capsids
equivalent to 13.2 mg) adjuvanted with montanide ISA720. When
analyzed two weeks after the last immunization, all animals
developed HPV16/31 L2-specific antibodies with titers around
100,000 (figure 7A). The antibodies neutralized PsV of HPV16
and HPV31 at dilutions higher than 1:1000 (figure 7B). Cross-
neutralizing titer against HPV18 was similar, whereas cross-
neutralization of HPV45, HPV52 and HPV58 PsV was lower but
still significant. These data support the high and broad reacting
immune response induced by AAVLP(HPV16/31L2) particles
also in this animal model.
To test whether the rabbit sera raised against AAVLP(HPV16/
31L2) confer protection against HPV16 infection, in an in vivo
model, rabbit sera were administered intraperitoneally to naı ¨ve
mice. Rabbit sera against AAVLP with an epitope of the
cholesteryl ester transfer protein (AAVLP TP18) were used to
detect the unspecific effect of AAVLP induced antibodies. Vaginal
infection of mice is detected three days after challenge as
luminescence signal after injection of the challenged mice with
luciferin. The passive transfer of AAVLP(HPV16/31L2) sera
protected mice from vaginal challenge with HPV16 PsV, whereas
the AAVLP TP18 control serum failed to protect the mice
(figure 7C). Protection by AAVLP(HPV16/31L2) sera was similar
to RG-1, a neutralizing monoclonal antibody recognizing the L2
17–36 motif.
Discussion
The first steps in papillomavirus infection involve L1 dependent
binding of the viral capsid to heparan sulfate proteoglycan [26]
and lamin 5 in the extracellular matrix [27] which induces
a conformational change leading to the exposure of L2, furin
dependent proteolytic processing and attachment to keratinocytes
[28,29]. Intervention with this infection pathway by prophylactic
vaccination has two possible targets, the L1 or the L2 protein of
the HPV capsid. While L1 antibodies are able to prevent both
steps – attachment to basal membrane and to keratinocytes – L2
antibodies can interfere only with binding to the keratinocytes. L1
antibodies can be induced to high neutralization titers, especially
when generated by HPV-VLPs, however, they have the drawback
of HPV-type restriction. Furthermore, L1 VLPs are expensive to
produce, especially for highly multivalent vaccines, and distribu-
tion of such vaccines requires a cold chain which limits their
adoption by developing countries. Thus, although two approved
L1 HPV-VLP vaccines – Gardasil
TM and Cervarix
TM – are highly
protective against the main high-risk HPV infections, they lack
cross-protection against other, more rare high-risk HPV types,
they are not heat stable and are expensive to produce. L2 vaccines
on the other hand, are able to expand the cross-protection profile
due to extensive homology of the N terminus of L2 [30]. In
particular, oligopeptides of the L2 proteins are sufficient to induce
a broadly cross-neutralizing immune response [31]. However,
neutralizing titers generated by L2 peptides are relatively low
compared to those produced by L1VLPs [32].
Several attempts have been made to improve the immunoge-
nicity of L2. These include insertion of L2-neutralizing epitopes on
the surface of HPV VLPs [9,33], construction of tandem repeats of
one peptide on bacterial thioredoxin [3] or concatenated L2
peptides from different papillomavirus types [11]. We have chosen
AAVLPs as a platform for presentation of a cross-neutralizing L2
epitope (aa 17–36). AAV capsids tolerate insertion of peptides at
different positions of the capsid and can be produced in large
quantities from only one capsid protein making it a simple, non-
infectious, empty capsid vaccine molecule [13,18,19,20]. In this
first exploration of AAVLPs as a vaccine for generating a humoral
immune response, the anti-peptide titers obtained were remark-
ably high (in the range of 10
4 to 10
5) after two immunizations with
only 0.6 mg VLPs per dose. A third immunization only slightly
increased the anti-L2 peptide titers. Nevertheless, an adjuvant
seems to be required for AAVLP vaccination, because the
recombinant AAV capsid alone elicits only a weak or no innate
immune response. So far, only one alternative adjuvant (MPL) has
been tested which was not as effective as montanide. Other options
have still to be explored [34,35]. Pre-existence of anti AAV
antibodies which are highly prevalent in the human populations,
Figure 2. Detection of HPV16 L2-specific antibody titers in
C57BL/6 mice vaccinated with AAVLP(HPV16/31L2). C57BL/6
mice (5 per group) vaccinated twice intramuscularly with
AAVLP(HPV16/31L2) particles either with a low dose (LD) (1E+11
particles equivalent to 0.6 mg of protein) or high dose (HD) (5E+12
particles equivalent to 30 mg) with or without an adjuvant (+M)
(montanide ISA 51). As positive control, mice were immunized three
times subcutaneously with Thioredoxin-L2(20–38)3 (TrXL2) (50 mg).
wtAAVLP particles served as negative control. HPV16 L2-specific
antibodies were measured by GST-L2 ELISA six weeks after the first
immunization. Data of individual mice are shown. Mean titers of each
group are shown by horizontal bars. Data are expressed as the
reciprocal titers of individual mice.
doi:10.1371/journal.pone.0039741.g002
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immune response. This could be explained by improved, anti-
AAV antibody Fc-mediated uptake of AAVLPs by professional
antibody presenting cells. A particular advantage of AAVLPs is
their stability which allows lyophilization and rehydration [36].
Thus, lyophilization of AAVLPs likely permits storage and delivery
Figure 3. Detection of neutralizing and cross-neutralizing antibodies after vaccination with AAVLP(HPV16/31L2) in C57BL/6 mice.
A) Neutralizing antibodies in sera of immunized animals were analyzed by HPV16 and HPV31 pseudovirion infection assay. B) Cross-neutralizing
antibodies against HPV18, HPV45, HPV52 and HPV58 pseudovirions were detected by pseudovirion infection assay. Data of individual mice are
shown. Data are expressed as the reciprocal neutralization titer obtained by using a cut off of 50% neutralization activity by incubation with serial
dilutions from 1:40 to 1:30,720 of the sera. Mean titers of each group are shown by horizontal bars.
doi:10.1371/journal.pone.0039741.g003
AAVLP(HPV16/31L2) Particles as HPV Vaccine
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the need of a cold chain for vaccine distribution. This may be an
important cost factor in developing countries and should be
further explored.
The AAVLPs of this study can be produced by transient
transfection of one or two plasmids expressing the capsid protein
VP3 and the assembly activating protein AAP [13]. Under these
conditions production of 10
12 to 10
13 capsids/ml can be achieved.
Purification of the particles follows standard chromatography
procedures and does not constitute a bottle-neck for AAVLP
manufacturing. Co-expression of VP3 and AAP using baculovirus
based vectors in insect cells provides one possibility of scale-up for
Figure 4. Detection of AAV-specific antibodies in Balb/c mice. Ten Balb/c mice were immunized twice intranasally with AAV2 (1E+11 capsids).
Two (black bars) and four weeks (grey bars) after the first immunization sera was tested for detection of AAV-specific capsid antibodies using an AAV-
based ELISA. Data are expressed as reciprocal titers of individual animal.
doi:10.1371/journal.pone.0039741.g004
Figure 5. Detection of HPV16 L2-specific antibodies in Balb/c mice vaccinated with AAVLP(HPV16/31L2). Mice were immunized with
low dose of AAVLP(HPV16/31L2) particles either twice (LD+M 2x) or three times (LD+M 3x) i.m. together with montanide ISA51 as an adjuvant. A
group of animals were vaccinated three times intramuscularly (i.m.) with low dose of AAVLP(HPV16/31L2) particles together with monophosphoryl
Lipid A (MPL) as an adjuvant (LD+MPL). In addition, one group of mice was immunized with three low doses of the lyophilized AAVLP(HPV16/31L2)
particles in combination with montanide ISA51 (Lyophilized). Four weeks after vaccination with AAV2 a group of animals were i.m. vaccinated with
AAVLP(HPV16/31L2) three times with montanide ISA51 (AAV preimmune). Animals vaccinated 3 times subcutaneously (s.c.) with thioredoxin-L220–38
(50 mg) plus montanide ISA51 (TrXL2+ M) and a group of animals immunized with Cervarix
TM and Gardasil
TM were used as controls. Six weeks after
the first immunization HPV16 L2-specific antibodies were detected by GST-L2 ELISA. Data of individual mice are shown. Mean titers of each group are
shown by horizontal bars.
doi:10.1371/journal.pone.0039741.g005
AAVLP(HPV16/31L2) Particles as HPV Vaccine
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PLoS ONE | www.plosone.org 7 June 2012 | Volume 7 | Issue 6 | e39741Figure 6. Detection of neutralizing and cross-neutralizing antibodies after vaccination of Balb/c mice with AAVLP(HPV16/31L2). A)
Neutralizing antibodies in sera of immunized Balb/c animals were analyzed by HPV16 and HPV31 pseudovirion infection assay. B) Cross-neutralizing
antibodies against HPV18, HPV45, HPV52, HPV58 and BPV pseudovirions were detected by pseudovirion infection assay. Data of individual mice are
shown. Data are expressed as the reciprocal neutralization titer obtained by using a cut off of 50% neutralization activity by incubation with serial
dilutions of the sera. Mean titers of each group are shown by horizontal bars.
doi:10.1371/journal.pone.0039741.g006
Figure 7. Immunoresponse of AAVLP(HPV16/31L2) in rabbits. Three rabbits were immunized i.m. four times with AAVLP(HPV16/31L2)
particles (2E+12 capsids equivalent to 13.2 mg) together with montanide ISA720 as an adjuvant. A) Ten weeks after the first immunization sera was
analyzed by an L2 peptide-based ELISA to detect HPV16 and HPV31 L2-specific antibodies. B) The presence of neutralizing and cross-neutralizing
antibodies against six different HPV types (HPV16, 18, 31, 45, 52, 58) was measured by pseudovirion-based neutralization assay (PBNA). C) Naı ¨ve Balb/
c mice were injected i.p. with 100 ml buffer, 20 mg RG-1 purified monoclonal antibody or rabbit antiserum to AAVLP TP18 or serum from three
different rabbits vaccinated with AAVLP(HPV16/31L2). One day later, the mice were vaginally challenged with HPV16 pseudovirus carrying a luciferase
reporter. At three days post challenge, infection was assessed by imaging luciferase activity.
doi:10.1371/journal.pone.0039741.g007
AAVLP(HPV16/31L2) Particles as HPV Vaccine
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AAVLP production, e.g. using bacteria or yeast, have still to be
explored.
Immunization with AAVLPs containing the insertion of two
different L2 peptide sequences at two separate positions of the
same capsid provided a broadly cross-neutralizing antiserum, as
tested in a pseudovirion (PsV) infection assay. This was observed
in C57BL/6 mice, Balb/c mice and in rabbits. The HPV16-L2
peptide inserted at 587 provided nearly 100% protection against
HPV16 PsV infection with rather high neutralizing antibody
titers. This was not the case for the HPV31-L2 peptide inserted
at aa position 453 and tested in the HPV31 PsV-based
neutralization assay. The result is in agreement with the study
of Jagu et al. that showed that a multitype L2 fusion protein
which included a peptide of HPV31 induced robust antibody
titers against various HPV types, but had relatively low titers
against HPV31 [11]. However, also the position of peptide
insertion in the AAV capsid may play a role. Peptides at position
453 are more exposed on the AAV capsid surface and have
a larger interpeptide distance at the threefold symmetry axis of
AAV2 than peptides inserted at aa 587. Immunization with the
same peptides inserted at the reversed positions should show
whether the inherent immunogenicity of the two peptides or the
localization on the capsid surface is responsible for the difference
in the immune reaction. Such an analysis might provide valuable
information for the optimal spatial arrangement of antigenic
epitopes on viral scaffolds for vaccination.
Because vaccination at low dose applies only 0.6 mgo f
AAVLPs/dose, a number of combinations of different AAVLPs
can be tested for optimization of the vaccine. This includes also
combinations of different AAVLPs with insertions of different
HPV-L2 peptides at one position or combined at two positions.
Another option would be the insertion of L2 peptides into other
immunogenic sites of the AAV capsid [38]. Furthermore, the
combination of peptide insertions with the expression of antigens
by gene transfer may provide a basis for a combined prophylactic
and therapeutic vaccine.
Cross-neutralizing vaccines against HPV types may not only be
prophylactic for cervical cancer and genital warts, but may also
have an impact on the prevention of a subset of head and neck or
skin cancers for which a causal role of certain HPV types has been
described. In general, this study describes the potential of AAVLPs
as a vaccination option for prevention of infection associated
diseases upon insertion of the appropriate linear protective
epitope.
Materials and Methods
Ethics Statement
All animal procedures were performed according to approved
protocols and in strict accordance with institutional and national
guidelines; Federal law and the standard ethical guidelines (NIH,
1985; European Communities Directives, 1986 86/609/EEC) and
approved by local government authorities (Regierungspra ¨sidium
Karlsruhe, Germany), guide for the Care and Use of Laboratory
Animals of the National Institutes of Health, with the prior
approval of the Animal Care and Use Committee of Johns
Hopkins University. All immunizations were performed under
ketamine anesthesia as describe below, and all efforts were made
to minimize suffering.
Cell Lines and Culture Conditions
Human embryonic kidney (HEK) 293T cells [39], and 293TT
cells [40] were maintained in Dulbecco modified Eagle medium
(DMEM) supplemented with 10% heat-inactivated fetal-calf
serum, 100 U of penicillin/ml, and 100 mg of streptomycin/ml
at 37uCi n5 %C O 2. The HeLaT cell line was generated by
transfecting a linearized expression plasmid with T-Ag under the
CMV promoter, followed by selection with hygromycin. Several
clones were screened with pseudovirions for best luciferase
transduction.
Animals
C57BL/6 (H-2b) and Balb/c female mice at 6–8 weeks of age
were purchased from Charles River Wiga (Sulzfeld, Germany) and
kept in an isolator at the animal facilities of the DKFZ. ZIKA
hybrid rabbits were purchased from Dr. Zimmermann GbR
(Abtsgmu ¨nd- Untergro ¨ningen, Germany) and housed at the
company BioGenes (Berlin, Germany). For HPV challenging
female Balb/c (6–8 weeks old) were purchased from the National
Cancer Institute (Frederick, MD, USA) and kept in the animal
facility of the Johns Hopkins School of Medicine (Baltimore, MD,
USA).
Cloning of AAVLP(HPV16/31L2)
AAVLP particles were generated from a plasmid containing the
overlapping AAV2 VP2 and VP3 coding sequence cloned into the
XhoI and NotI site of the pCI plasmid (Promega, Madison, WI).
The start codon of VP2 was destroyed by introducing a point-
mutation using the Quick Change Site-Directed Mutagenesis kit
(Agilent Technologies, La Jolla, CA). A FseI site was introduced
without changing the VP3 protein sequence at position 520 (amino
acid number relative to the VP1 protein of AAV2) to generate the
plasmid pCIVP2mut. In order to introduce peptides into VP3 the
plasmid pCIVP2mut was modified. The plasmid pCIVP2mut-
I587 was generated by introduction of NotI and BspEI sites at
position 587. A second plasmid, pCIVP2mut-I453, was generated
by introduction of NotI and BspEI sites at position 453. The
nucleotide sequence of L2 residues 17 to 36 of HPV16 was cloned
into the NotI/BspEI digested pCIVP2mut-I587 and the nucleotide
sequence of L2 residues 17 to 36 of HPV31 into the NotI/BspEI
digested pCIVP2mut-I453. Subsequently a fragment containing
the HPV31 L2 sequence was generated by digestion of
pCIVP2mut-I453 with BsiWI/FseI. The fragment was subcloned
into the BsiWI/FseI digested pCIVP2mut-I587 and finally
arginines at position 585 and 587 were substituted by alanine
residues to generate the plasmid for the AAVLP(HPV16/31L2)
production.
Production and Purification of AAVLP(HPV16/31L2)
293T cells were transfected with AAVLP(HPV16/31L2)
plasmid DNA (36 mg per 15 cm dish). Transfected cells were
harvested after 3 days and lysed by three freeze-thaw cycles. The
medium was cleared by filtration and adjusted to pH to 6.0 in
HEPES buffer. Particles were further purified through chroma-
tography. Briefly, the diluted cleared lysate containing the AAVLP
particles was loaded onto Fractogel EMD SO3 column and after
washing with HEPES buffer were eluted with 0.6 M NaCl. After
buffer exchange the particles were processed through CaptoQ
column (GE Healthcare). The particles in the flow-through, were
concentrated and separated through a Superdex 200 column (GE
Healthcare). Fractions containing AAVLP(HPV16/31L2) particles
(analyzed by SDS-PAGE) were pooled and sterile filtrated. The
particle titer was determined using the AAV2 titration ELISA
(Progen, Heidelberg, Germany). Endotoxin concentration was
measured using the turbimetric kinetic LAL test (BSL Bioservice,
Planegg, Germany).
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Expression of the AAVLP(HPV16/31L2) VP3 proteins was
verified by Western blotting using the monoclonal antibody B1
(diluted 1:200, Progen). The blotted membrane was incubated
with 5% skim milk in 1 x PBS/0.05% Tween-20 for 1 h at RT
followed by incubation of the membrane with antibody B1 for 1
hour at RT. After washing bound antibodies were detected with
1:2,500 diluted HRP-labeled anti-mouse IgG (DAKO, Glostrup,
Denmark). The expression of the AAVLP HPV16 and HPV31 L2
inserted peptides was analyzed by native dot blotting. Two mg
(3E+11 particles) of the AAVLP(HPV16/31L2) particles, 2 mgo f
AAVLP particles without inserts or 10 mg of the HPV16 and 31
L2 peptides QLYKTCKQAGTCPPDIIPKV and QLYQTCK-
AAGTCPSDVIPKI were dotted on a nitrocellulose membrane
that was incubated with 1:1,000 diluted rabbit sera for 1 hour at
RT. Bound antibodies were detected with 1:2,500 diluted HRP-
labeled anti-rabbit IgG (DAKO, Glostrup, Denmark).
Lyophilization
Lyophilization of particles in 600 mM mannitol dissolved in
Hepes buffer pH 6.0 with 200 mM NaCl was carried out using
Epsilon 2-12D freeze-drier (Martin Christ Freeze Dryers GmbH,
Osterode, Germany) stored at #20uC until use.
TEM
Transmission electron microscopy (TEM) of the purified
AAVLP(HPV16/31L2) particles was performed after fixation
2.5% glutardialdehyde and stained with 2% uranium acetate and
0.01% glucose (performed by Prof. Dr. Wanner at the LMU
Munich, Germany).
AAV2 Empty Capsid Production
Particles were produced as described previously in [36]. Briefly,
293T cells were infected with a recombinant adenovirus expres-
sing VP1, VP2 and VP3 of AAV2. Cells were harvested and
fractionated on a sucrose cushion by under laying the supernatant
with 450 ml of 30% sucrose (in Tris-EDTA) followed by 450 mlo f
50% sucrose in Tris-EDTA. The gradients were centrifuged at
273,0006g for 2.5 h at 4uC by using an SW60 rotor (Beckman,
Germany). The pellet was resuspended in TBSM buffer and
purified on a second sucrose cushion. The resulting pellet was
resuspended in an appropriate volume of TBSM buffer and then
analyzed by electron microscopy.
Immunization of Animals
Female mice were kept under deep ketamine 10%/rompun 2%
(Bayer) anesthesia by intraperitoneal injection. Low doses (1E+11
particles/dose) or High doses (5E+12 particles/dose) of
AAVLP(HPV16/31L2) were delivered intramuscularly into the
tibia anterior muscle of the right leg with or without adjuvant.
Two weeks later a boost was administrated in the same way. In
case of TrX-L2 immunization, 50 mg of filter-sterilized TrX-
L2(20–38)3 [3] mixed with adjuvant was applied subcutaneously.
Two and four weeks later, two boosts were administrated in the
same way. Samples of blood were collected 45 days after the first
immunization. All samples were stored at 220uC. Female rabbits
were immunized intramuscularly with 2E+12 capsids/dose in a 1:2
mixture of montanide ISA720, followed by boosts two weeks, five
weeks and eight weeks later (BioGenes). Sera were collected 14
days after the last boost and stored at 220uC. For control purposes
one female rabbit was immunized with AAVLPs containing an
epitope of the cholesteryl ester transfer protein (AAVLP TP18)
[41].
Adjuvants
Montanide ISA51 and montanide ISA720 were obtained from
Seppic (Paris, France). A mixture of 1:1 (ISA51) or 1:2 (ISA720)
with the antigen was applied per dose. Five micrograms of
monophosphoryl lipid A derived from Salmonella enterica (MPL) in
2% squalene oil-in-water emulsion (Sigma Adjuvant System,
Sigma, St. Louis, MA) were applied per dose.
Measurement of Antibody Responses
The presence of HPV16 L2-specific IgG antibodies in sera of
immunized mice was determined by GST L2-ELISA as described
[3]. To detect anti-AAV antibodies sera (in 2-fold dilutions starting
from 1:50 to 1:500,000) were added into AAV2 pre-coated plates
(10
10 particles/well). HRP-coupled antimouse IgG was used as
secondary antibody (dil 1:5000, Southern Biotechnology, Birming-
ham, MA). TMB (Sigma) substrate solution was used as substrate
OD was measured in an ELISA reader at 450 nm. Nonspecific
binding was determined by using the same dilutions on plates
coated with PBS only. The presence of HPV16 and HPV31 L2-
specific IgG antibodies in sera of immunized rabbits was
determined by L2 peptide-ELISA. 96-well plates were coated
with 1 mg/well of the peptides QLYKTCKQAGTCPPDIIPKV
or QLYQTCKAAGTCPSDVIPKI in PBS overnight at 4uC and
blocked with 5% skim milk in PBS-T for 1 h at 37uC. The
peptides were incubated with serial dilutions of the sera (3-fold
dilutions starting from 1:1,000 to 1:2,187,000) in PBS-T with 1%
skim milk and 1% BSA for 1 h at 37uC. Rabbit pre- immune sera
were diluted 1:1,000. Bound rabbit IgGs were detected after
incubation with a 1:2,500 diluted HRP-labeled anti-rabbit IgG
(DAKO) antibody following the same conditions as above.
Pseudovirion-based Neutralization Assay
Neutralizing antibodies in sera of immunized animals were
determined as described previously [4] but with pseudovirions
(PSV) expressing gaussia luciferase (gLuc) as reporter. Briefly, PsV
were prepared by transfecting 293TT cells with a plasmid
encoding for the humanized HPV16 L1 and L2 genes, together
with a plasmid containing the gene for gLuc under the control of
CMV promoter. For PsV extraction, 293TT cells were harvested
and washed once with 1 ml of Dulbecco’s Phosphate Buffered
Saline (DPBS; Gibco). The cell pellet was resuspended in 150 mlo f
lysis buffer (140 ml DBPS, 9 ml 10% Brij58 (w/v) (Sigma) and 1 ml
RNAse A/T cocktail (Fermentas)). The PsV-containing superna-
tant was set aside and the cell pellet was resuspended anew in
300 ml DPBS/0.8 M NaCl. Samples were cleared by centrifuga-
tion at 10,000 rpm and 4uC for 10 minutes. The supernatants
were combined, 2 ml benzonase were added and the samples were
incubated for 1 hour at 37uC. The PsV were Optiprep purified
and used for infection of HeLaT cells.
Sera were transferred to 384 well polypropylene V-bottom
plates (Greiner) and serially diluted ten times in 2-fold increments
from 1/3 to 1/1536. Each 2 ml of the serially diluted sera were
transferred to 21 white 384 well cell culture plates (PerkinElmer)
with an EP3 384-head pipetting robot (Perkin Elmer), the plates
immediately sealed with a polypropylene cover foil and stored at
220uC.
In Vivo Pseudovirus Delivery and Infection
HPV16 pseudovirions with encapsulated luciferase reporter
were generated by cotransfection of 293TT cells with plasmids
encoding codon-modified L1 and L2 and a firefly luciferase
reporter plasmid, as described previously [40]. Female Balb/c
mice were treated with 3 mg of Depo-provera (Pfizer) 4 days prior
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i.p. with buffer, undiluted rabbit antisera or 20 mg of purified RG-
1 monoclonal antibody. The mice were anesthetized and
challenged with pseudovirus as previously described [42], but
with modifications. Briefly, a HPV16 PsV inoculum of 20 ml
mixed with 20 ml of a 3% CMC preparation, based on L1 content,
was used. The inoculum was delivered using an M20 positive-
displacement pipette in two doses; 20 ml before and 20 ml after
insertion in the vagina of a Cytobrush that was turned clockwise
and counterclockwise 10 times. After the challenge, standard
dissecting forceps were used to occlude the vaginal introitus to
achieve maximal retention of the material while the mice recover
from anesthesia. Three days after pseudovirion challenge, the mice
were again anesthetized and 20 ml of luciferin (7.8 mg/ml) was
deposited in the vaginal vault. Luciferase signals were acquired for
10 min with a Xenogen IVIS 100 imager, and analysis was
performed with Living Image 2.0 software (Caliper Life Sciences).
An identical region of interest (ROI) was drawn around the
luciferase signal emitted from each mouse, and the average
radiance within the ROI was determined.
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